Clinical Trial Update: A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye. [Phase 1, Phase 2]

View source ↗

Summary

Pfizer's JAK inhibitor CP-690,550 (tofacitinib) was studied in a randomized, placebo- and active-controlled Phase 1/2 trial in adults with dry eye; the results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• CP-690,550 (tofacitinib) (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Dry Eye Syndromes | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-04-09